Clinical trial information
Select trial for more information
- Overview
- Clinical Trials
- Abbreviations
Target Overview
The cytokine IL-2 is a critical regulator of immune cell function and promotes anti-tumour immunity via T cell proliferation, survival and effector function. IL-2 is a clinically validated immunotherapy1-3 but the optimal approach to delivering IL-2 to cancer cells has yet to be achieved.
Compound Overview
AZD6750 applies cis-guiding to deliver a modified IL-2 mutein preferentially to CD8+ T cells. This approach may improve the therapeutic index of IL-2 by maintaining CD8+ T cell driven efficacy whilst limiting side effects attributed to broad IL-2R signalling4.
Mechanism of Action
References
1. Fishman M, Dutcher JP, Clark JI, et al. J Immunother Cancer. 2019;7(1):84. 2. Klapper JA, Downey SG, Smith FO, et al. Cancer. 2008;113(2):293-301. 3. Bright R, Coventry BJ, Eardley-Harris N, Briggs N. J Immunother. 2017;40(1):21-30. 4. Elder MJ, Riley AH, Tan SL, et al. J Immunother Cancer. 2025;13.
Arrange By
Selected Filter(s)
Abbreviations
CD8+
cluster of differentiation 8+
GC/GEJC
gastric cancer/gastroesophageal junction cancer
HNSCC
head and neck squamous cell carcinoma
HGSOC
high grade serous ovarian carcinoma
IL-2
interleukin-2
IL-2R
interleukin-2 receptor
MCC
merkel cell carcinoma
MEL
melanoma
NSCLC
non-small cell lung cancer
RCC
renal cell carcinoma
SCC
squamous cell carcinoma
T cell
T lymphocyte
TNBC
triple-negative breast cancer
Target Overview
The cytokine IL-2 is a critical regulator of immune cell function and promotes anti-tumour immunity via T cell proliferation, survival and effector function. IL-2 is a clinically validated immunotherapy1-3 but the optimal approach to delivering IL-2 to cancer cells has yet to be achieved.
Compound Overview
AZD6750 applies cis-guiding to deliver a modified IL-2 mutein preferentially to CD8+ T cells. This approach may improve the therapeutic index of IL-2 by maintaining CD8+ T cell driven efficacy whilst limiting side effects attributed to broad IL-2R signalling4.
Mechanism of Action
References
1. Fishman M, Dutcher JP, Clark JI, et al. J Immunother Cancer. 2019;7(1):84. 2. Klapper JA, Downey SG, Smith FO, et al. Cancer. 2008;113(2):293-301. 3. Bright R, Coventry BJ, Eardley-Harris N, Briggs N. J Immunother. 2017;40(1):21-30. 4. Elder MJ, Riley AH, Tan SL, et al. J Immunother Cancer. 2025;13.
Clinical trial information
Select trial for more information
Arrange By
Selected Filter(s)
Abbreviations
CD8+
cluster of differentiation 8+
GC/GEJC
gastric cancer/gastroesophageal junction cancer
HNSCC
head and neck squamous cell carcinoma
HGSOC
high grade serous ovarian carcinoma
IL-2
interleukin-2
IL-2R
interleukin-2 receptor
MCC
merkel cell carcinoma
MEL
melanoma
NSCLC
non-small cell lung cancer
RCC
renal cell carcinoma
SCC
squamous cell carcinoma
T cell
T lymphocyte
TNBC
triple-negative breast cancer